SAN DIEGO, California, October 1, 2026
Halozyme Therapeutics, Inc. announced the appointment of Jim Daly to its Board of Directors, effective immediately. Daly brings extensive experience in the biopharmaceutical industry, including leadership roles spanning commercial operations, global product launches, business development and corporate strategy. His appointment adds another experienced industry executive to Halozyme’s board as the company continues advancing its proprietary ENHANZE® drug delivery technology and expanding collaborations with pharmaceutical and biotechnology partners. Halozyme is a biopharmaceutical company focused on developing and commercializing novel drug-delivery solutions designed to improve the administration of injectable medicines. The company’s ENHANZE technology is based on recombinant human hyaluronidase and is designed to facilitate the subcutaneous delivery of large-volume and biologic medicines, potentially reducing administration time and supporting alternative treatment settings. Daly’s experience in building pharmaceutical franchises and leading commercial organizations is expected to contribute to the company’s strategic and operational oversight as Halozyme continues to expand its technology platform and partnered portfolio.
Jim Daly Brings Extensive Biopharma Experience
Jim Daly has held senior leadership positions across the biopharmaceutical sector and has experience in commercializing medicines across multiple therapeutic areas and global markets. During his career, he served in senior executive positions at Amgen, where he was responsible for commercial operations and contributed to the development and growth of major pharmaceutical products. Daly also previously served as Chief Commercial Officer at AstraZeneca, where he played a role in global commercial strategy and product development activities. His professional background includes experience in sales, marketing, market access, business development and global pharmaceutical operations, providing a broad perspective relevant to Halozyme’s growth strategy. Halozyme said Daly’s experience will strengthen the board’s capabilities as the company continues to pursue opportunities for its drug-delivery technologies and work with pharmaceutical partners to advance injectable medicines.
Halozyme Expands ENHANZE Drug Delivery Platform
Halozyme’s core technology is ENHANZE, a drug-delivery platform designed to enable the subcutaneous administration of medicines that may otherwise require intravenous infusion or other administration approaches. The technology uses a proprietary recombinant human hyaluronidase enzyme to temporarily modify the extracellular matrix in the tissue under the skin, allowing injected medicines to disperse more readily. This approach has been incorporated into multiple partnered pharmaceutical products and continues to be evaluated across additional therapeutic programs. By supporting subcutaneous delivery, ENHANZE has the potential to contribute to shorter administration times and greater flexibility for patients and healthcare providers, depending on the specific medicine and approved product formulation. Halozyme continues to collaborate with pharmaceutical companies on applications of the technology across areas including oncology, immunology and other chronic diseases.
Advertisement
Board Appointment Supports Long-Term Strategy
The appointment of Daly comes as Halozyme continues to focus on technology partnerships, product commercialization and long-term growth. The company has established a business model centered on licensing its drug-delivery technology to pharmaceutical partners, allowing ENHANZE to be incorporated into medicines developed and commercialized by other companies. This strategy has enabled Halozyme to participate in multiple pharmaceutical programs while maintaining its focus on advancing its proprietary delivery platform. Daly’s background in global pharmaceutical commercialization provides additional expertise as Halozyme evaluates new opportunities and supports the expansion of its partnered programs. The company said his experience in developing commercial strategies and bringing innovative medicines to patients will complement the expertise of the existing board. Halozyme’s board appointment therefore represents a corporate leadership development relevant to the company’s ongoing biopharmaceutical technology and drug-delivery strategy. As the company continues expanding its ENHANZE platform and working with pharmaceutical partners, the addition of an executive with extensive industry and commercialization experience strengthens the board’s collective expertise. The appointment also reflects the increasing importance of alternative drug-delivery technologies in the biopharmaceutical industry, where subcutaneous formulations can provide new administration options for certain complex injectable medicines.
Source: Halozyme Therapeutics press release
